Status:

COMPLETED

Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.

Lead Sponsor:

Fundación GECP

Conditions:

Small Cell Lung Cancer (SCLC)

Eligibility:

All Genders

18+ years

Brief Summary

This is a non-interventional, observational, multicentre, one-arm, non-comparative, and retrospective study. The study is based on the collection of data about the patients treated with Durvalumab af...

Detailed Description

Lung Cancer represent approximately 13% of total cancer diagnoses worldwide and continues to be the leading cause of cancer-related mortality. Stage III represents between 25-30% of NSCLC and the majo...

Eligibility Criteria

Inclusion

  • Patients must have histologically or cytologically documented diagnosis of NSCLC with a locally advanced, or locally recurrent, unresectable (stage III) disease (according to American Joint Committee on Cancer \[AJCC\] lung cancer edition 7 or 8).
  • Age ≥ 18 years at time of study Entry
  • Patients must have been treated with chemotherapy and radiotherapy concurrently or sequentially and shown no progressive disease following chemoradiation
  • Patients must have been enrolled in durvalumab EAPs between 1 September 2017 and 21 December 2018.
  • Patients must have been treated with at least one dose of durvalumab within the EAP
  • Alive patients must have signed, dated and IRB/EC-approved written informed consent\* form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.

Exclusion

  • Alive patients who do not want to sign and date an IRB/IEC-approved written informed consent form.
  • Patients who were accepted in the EAP, but did not receive treatment.
  • Patients treated with durvalumab in clinical studies prior to the index date (first dose of durvalumab received within the EAP

Key Trial Info

Start Date :

May 21 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 31 2021

Estimated Enrollment :

245 Patients enrolled

Trial Details

Trial ID

NCT04285866

Start Date

May 21 2020

End Date

December 31 2021

Last Update

June 7 2022

Active Locations (39)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (39 locations)

1

Hospital Clínico Universitario de Santiago

Santiago de Compostela, A Coruña, Spain, 15706

2

Hospital Universitario Son Llàtzer

Palma de Mallorca, Balearic Islands, Spain, 07198

3

Hospital Universitari Germans Trias i Pujol

Badalona, Barcelona, Spain, 08916

4

Hospital General de Granollers

Granollers, Barcelona, Spain, 08402